SCHEMBL1628514

SCHEMBL1628514

O=S(=O)(Oc1ccc2cc(C3CCCC3)ccc2c1)C(F)(F)F

nearest known ligand 0.52

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 6/20 0.49
DRD3 P35462 6/20 0.49
DRD1 P21728 5/20 0.49
DRD4 P21917 5/20 0.49
DRD5 P21918 5/20 0.49
HSD11B1 P28845 1/20 0.42
HTR1D P28221 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
BACE1 P56817 1/20 0.39
ABL1 P00519 2/20 0.39
ACMSD Q8TDX5 2/20 0.38
STS P08842 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3128608 0.86 DRD2 (0.61) DRD2DRD3DRD1DRD4DRD5
SCHEMBL9957718 0.84 DRD2 (0.60) DRD2DRD3DRD1DRD4DRD5
SCHEMBL15912455 0.84 DRD2 (0.46) DRD2DRD3DRD1DRD4DRD5
SCHEMBL10180323 0.84 DRD2 (0.65) DRD2DRD3DRD1DRD4DRD5
SCHEMBL3158316 0.83 DRD2 (0.48) DRD2DRD3DRD1DRD4DRD5
SCHEMBL3160924 0.83 DRD2 (0.48) DRD2DRD3DRD1DRD4DRD5
SCHEMBL10180668 0.82 DRD2 (0.63) DRD2DRD3DRD1DRD4DRD5
SCHEMBL7667692 0.81 DRD2 (0.56) DRD2DRD3DRD1DRD4DRD5
SCHEMBL4056753 0.80 CA1 (0.51) DRD2DRD3HSD11B1HTR1DCA1
SCHEMBL21332379 0.80 DRD2 (0.47) DRD2DRD3DRD1DRD4DRD5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210122978-A1 Liquid Crystals Comprising Cyclopentane Groups VVI BRIGHT CHINA LTD (CN) 2021-04-29 US disclosed
US-10745617-B2 Liquid crystals comprising cyclopentane groups VVI BRIGHT CHINA LTD (CN) 2020-08-18 US disclosed
US-20180163131-A1 LIQUID CRYSTALS COMPRISING CYCLOPENTANE GROUPS VVI BRIGHT, INC. 2018-06-14 US disclosed
US-20180163131-A1 LIQUID CRYSTALS COMPRISING CYCLOPENTANE GROUPS VVI BRIGHT, INC. 2018-06-14 US disclosed
US-9822303-B2 Liquid crystals comprising cyclopentane groups VVI BRIGHT CHINA LTD (CN) 2017-11-21 US disclosed
US-9822303-B2 Liquid crystals comprising cyclopentane groups VVI BRIGHT CHINA LTD (CN) 2017-11-21 US disclosed
US-9822303-B2 Liquid crystals comprising cyclopentane groups VVI BRIGHT CHINA LTD (CN) 2017-11-21 US disclosed
US-20160237348-A1 LIQUID CRYSTALS COMPRISING CYCLOPENTANE GROUPS VVI BRIGHT, INC. 2016-08-18 US disclosed
US-20160237348-A1 LIQUID CRYSTALS COMPRISING CYCLOPENTANE GROUPS VVI BRIGHT, INC. 2016-08-18 US disclosed
US-20160237348-A1 LIQUID CRYSTALS COMPRISING CYCLOPENTANE GROUPS VVI BRIGHT, INC. 2016-08-18 US disclosed
US-20150034872-A1 LIQUID CRYSTALS COMPRISING CYCLOPENTANE GROUPS VVI BRIGHT, INC. 2015-02-05 US disclosed
US-20150034872-A1 LIQUID CRYSTALS COMPRISING CYCLOPENTANE GROUPS VVI BRIGHT, INC. 2015-02-05 US disclosed
US-20150034872-A1 LIQUID CRYSTALS COMPRISING CYCLOPENTANE GROUPS VVI BRIGHT, INC. 2015-02-05 US disclosed
US-8801966-B2 Liquid crystals comprising cyclopentane groups VVI BRIGHT CHINA LTD. (CN) 2014-08-12 US disclosed
US-8801966-B2 Liquid crystals comprising cyclopentane groups VVI BRIGHT CHINA LTD. (CN) 2014-08-12 US disclosed
US-8801966-B2 Liquid crystals comprising cyclopentane groups VVI BRIGHT CHINA LTD. (CN) 2014-08-12 US disclosed
US-20110089374-A1 Liquid Crystals Comprising Cyclopentane Groups VVI BRIGHT, INC. (US) 2011-04-21 US disclosed
US-20110089374-A1 Liquid Crystals Comprising Cyclopentane Groups VVI BRIGHT, INC. (US) 2011-04-21 US disclosed
US-20110089374-A1 Liquid Crystals Comprising Cyclopentane Groups VVI BRIGHT, INC. (US) 2011-04-21 US disclosed
WO-2009100204-A1 LIQUID CRYSTALS COMPRISING CYCLOPENTANE GROUPS VVI BRIGHT, INC. (US) 2009-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150034872-A1 LIQUID CRYSTALS COMPRISING CYCLOPENTANE GROUPS CXCR5, CCL5, ELOC DRD2 1293/4885DRD3 826/4885DRD1 1271/4885
US-20210122978-A1 Liquid Crystals Comprising Cyclopentane Groups CXCR5, CCL5, ELOC DRD2 1293/4885DRD3 826/4885DRD1 1271/4885
US-10745617-B2 Liquid crystals comprising cyclopentane groups CXCR5, CCL5, ELOC DRD2 1293/4885DRD3 826/4885DRD1 1271/4885
US-20180163131-A1 LIQUID CRYSTALS COMPRISING CYCLOPENTANE GROUPS CXCR5, CCL5, ELOC DRD2 1293/4885DRD3 826/4885DRD1 1271/4885
US-20110089374-A1 Liquid Crystals Comprising Cyclopentane Groups CXCR5, CCL5, ELOC DRD2 1293/4885DRD3 826/4885DRD1 1271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.